Conmind
Cardiovascular and Cerebrovascular Interventional Products R&D and Manufacturer
Recently, CONMIND MEDICAL, a star enterprise in the field of brain medical technology in China, announced the completion of a nearly 200 million RMB C-round financing.
This round of financing was led by Zhongshan Venture Capital's ZhongshanBiopharmaceuticalsLed by Angel Fund, with renowned institutions such as Yucai Zhongyin, Yueke Financial, Jingta Capital, and Jinhang Qiyi Fund following the investment. The existing shareholder, Zhuhai Gaoke Jintou, continues to increase its investment.
It is reported that the funds raised in this round will be mainly invested in the research and development of core brain-computer interface technologies, iteration of key components, and industrialization layout, accelerating the clinical large-scale application of interventional and invasive brain-computer interface products.
Conmind was founded in 2021. The core team has over 13 years of experience in the research and development of Class III implantable medical devices, with extensive capabilities in brain medicine resource integration and full-chain commercialization.
Among them, Huang Hui, the founder and CEO of CONMIND MEDICAL, has rich experience in interventional product management and the growth of start-up companies. He has served as the National Sales Manager of China for Broncus Medical, Marketing Director and Direct Sales Manager of MedSaint, and Regional Manager of Lifetech Scientific. All the products he managed during his tenure grew to become the first or second in their respective market shares in China.
Liu Xiangdong, CTO of Conmind, formerly served as the R&D Director of Lifetech Scientific Group and General Manager of CardioFlow Technology. He led the development of products such as coronary stents, occluders, vascular stents, heart valves, and neurointerventional devices, with corresponding product lines generating annual sales exceeding 400 million yuan. He has participated in multiple national and provincial-level major scientific and technological projects and obtained the China Quality Association's Six Sigma Black Belt Master certification.
Conmind, starting with cardiovascular and cerebrovascular interventional devices, has built a complete product matrix covering stroke and structural heart disease. In the field of neurointervention, it has developed flow-diverting stents, intracranial stents, coil embolization systems, and various types of catheters and guidewires. In cardiac intervention, the focus is on minimally invasive repair of the mitral and tricuspid valves; the self-developed transcatheter mitral chordae repair system has demonstrated clinical advantages such as minimal invasiveness and rapid recovery. The entire series is protected by independent intellectual property rights, with over 200 patent applications filed domestically and internationally. It has obtained 10 Class III medical device registration certificates in China, and the localization rate of core materials and equipment exceeds 95%.
At the same time, the company has not only completed its product layout but also established underlying capabilities in materials, precision processing, and delivery systems.
As a company focusing on the "simultaneous treatment of heart and brain," Conmind, relying on its accumulated expertise in precision devices for cardiovascular and cerebrovascular interventions, minimally invasive interventions, and neuromodulation technologies, has extended its reach to brain-computer interfaces. It proposes the core concept of "repairing the heart and protecting the brain," deeply integrating the treatment of cardiovascular and cerebrovascular diseases with neuromodulation. By entering the field of closed-loop neuromodulation therapies such as interventional brain-computer interfaces, Conmind has completed the layout of core components and foundational technologies, with its pipeline gradually moving into the clinical application verification stage.
In terms of technology, the focus is primarily on interventional or invasive approaches, with a strategic layout of technologies related to neuromodulation and functional reconstruction. The overall technological pathway is supported by minimally invasive interventional techniques and a brain-computer interface platform, targeting application scenarios related to neuromodulation and brain function.
As of now, the company has completed three rounds of financing, introducing multiple institutions such as Zhuhai Gaokexin Venture Capital, Qinzhi Capital, Turing Asset Management, Shanghai Bank International, Beijing Venture Capital, Yuecai Holdings, Jingtai Lifeng, Guangdong Science and Technology Finance Group, Zhongshan Financial Control, Zhuhai High-tech Investment, and Jinhang Industry. Among these, a nearly 100-million-yuan Series B round was completed in August 2023, and a Series B+ round was completed in November 2024. Overall, CONMIND MEDICAL's core competitiveness lies in its early completion of the leap from research and development to commercialization. After obtaining certification for its stroke-related products, the company quickly scaled up production, entering several top-tier tertiary hospitals in China while completing the construction of its nationwide commercial channels and initiating overseas market expansion. This "medical devices first, then brain-computer interface" development path has endowed it with stronger risk resistance in terms of cash flow, registration experience, and clinical resources, enabling it to support the long-cycle, high-investment R&D of brain-computer interfaces. Additionally, the capital injection at this stage also confirms its potential to move from technical validation to large-scale implementation.